About Publications

Publications from the National Academies of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes Health and Medicine Division (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.


  • Ethical Issues in Studying the Safety of Approved Drugs ... Released: July 09, 2010
    The side effects of some drugs may not appear until after the FDA has approved them. In this report, the IOM offers an ethical framework to help the FDA decide when to require clinical trials to assess a drug's safety after it is on the market.
  • Mental, Neurological, and Substance Use Disorders in Sub ... Released: July 08, 2010
    Millions of people in sub-Saharan Africa suffer from mental, neurological, and substance use (MNS) disorders, and most do not have the resources to obtain treatment. The Uganda National Academy of Sciences and the IOM hosted a workshop to discuss the state of care for MNS disorders in sub-Saharan Africa.
  • Leadership Commitments to Improve Value in Healthcare ... Released: June 14, 2010
    The U.S. health care system is large, dynamic, complex, and multifaceted. It consists of many participants often working in unassociated or fragmented ways that compromise the quality and value of care. The IOM hosted a workshop to discuss how to improve the efficiency and effectiveness of health care.
  • A Foundation for Evidence-Driven Practice: A Rapid Learning ... Released: June 04, 2010
    The IOM's National Cancer Policy Forum held a workshop October 5-6, 2009, to examine how to apply the concept of a "rapid learning health system" to the problem of cancer. This document summarizes the workshop.
  • Evaluation of Biomarkers and Surrogate Endpoints in Chronic ... Released: May 12, 2010
    Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.
  • CNS Clinical Trials: Suicidality and Data Collection ... Released: May 04, 2010
    The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior. The IOM’s Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA’s new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
  • Future Directions for the National Healthcare Quality and ... Released: April 14, 2010
    The Agency for Healthcare Research and Quality’s annual National Healthcare Quality Report (NHQR) and the National Healthcare Disparities Report (NHDR) reveal areas in which health care performance has improved over time and identify major shortcomings. The IOM concludes that the next generation of reports can be improved in ways that would make them more influential in promoting change in the health care system.
  • Policy Issues in the Development of Personalized Medicine in ... Released: February 08, 2010
    As cancer care becomes more personalized, patients will receive preventive or therapeutic interventions based on their susceptibilities or predicted responses. But before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of policy issues. To explore these policy challenges, the National Cancer Policy Forum held this workshop in June 2009.
  • Value in Health Care: Accounting for Cost, Quality, Safety ... Released: December 16, 2009
    The Roundtable on Evidence-Based Medicine held a workshop to facilitate public understanding and discussions of value in health care. This report summarizes the workshop discussions.
  • Assessing and Improving Value in Cancer Care. Workshop ... Released: November 04, 2009
    Like other areas of health care, oncology is under pressure to control expenses while improving patient outcomes and the quality of care. Unlike many other areas of health care, however, oncology faces unique challenges that can make it especially difficult to control costs. On February 9-10, 2009, the National Cancer Policy Forum held a workshop to explore these issues from multiple perspectives, including those of patients and patient advocates, providers, insurers, health care researchers, federal agencies, and industry. Assessing and Improving the Value in Cancer Care summarizes workshop discussions and presentations.